BUSINESS

Erbitux-Braftovi Combo Now Available for Frontline BRAF-Mutant Colorectal Cancer in Japan

December 9, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Merck Biopharma said on December 8 that its EGFR-targeting antibody Erbitux (cetuximab) can now be used in combination with Ono Pharmaceutical’s BRAF inhibitor Braftovi (encorafenib) plus chemotherapy as a first-line treatment for unresectable advanced or recurrent BRAF-mutant colorectal cancer in…

To read the full story

Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
November 21, 2025

BUSINESS

Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…